Why early matters
Every day of drift has a price.
Executives usually hear that a trial is late at a quarterly review, when the enrollment window or the data lock date has already moved. By then the cost is real. Tufts Center for the Study of Drug Development (Tufts CSDD) puts a figure on each day.
~$800K
Lost prescription drug or biologic sales for each day a product reaches market later
$55,716
Direct cost of one day of a Phase III trial (about $40,000 per day across Phase II and III)
260 days
Average time for one protocol amendment, from identifying the need to final approval
Sources: Smith, DiMasi, and Getz, Tufts CSDD Day of Delay white paper (2024); Tufts CSDD protocol amendment study, Therapeutic Innovation and Regulatory Science (2024).